Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DGAT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DGAT1 Recombinant Protein (Partial ECD) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View DGAT1 Products |
| Gene Delivery | DGAT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for functional multi-pass membrane conformation. |
View DGAT1 Products |
| Benchmark Ab | Anti-DGAT1 Recombinant Antibody Recombinant positive control for expression and localization assays. |
View DGAT1 Products |
| Validator | DGAT1 siRNA Set For knockdown verification in adipocytes and enterocytes. |
View DGAT1 Products |
| Related Target A | DGAT2 Functional isoform. Crucial for selectivity and counter-screening assays. |
View DGAT2 Products |
| Related Target B | ACC1 Upstream regulator of fatty acid synthesis, target for synergistic combination therapy. |
View ACC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane protein conformation | Lentivirus-driven stable cell line expression preserves native 11-transmembrane topology. |
| Isoform selectivity (DGAT1 vs DGAT2) | Highly characterized DGAT2 control reagents available for counter-screening panels. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live DGAT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DGAT1 therapeutics is intensifying, with major players shifting focus from traditional systemic small molecules to intestine-restricted inhibitors, topical formulations, and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting localized delivery to mitigate the gastrointestinal side effects historically associated with systemic DGAT1 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Systemic) | Novartis, AstraZeneca | NASH, Type 2 Diabetes | Selectivity Assay (Need Mutant vs WT Proteins & DGAT2 counter-screens) |
| Small Molecule (Topical) | Dermatology-focused biotechs | Acne Vulgaris, Seborrhea | Sebocyte Cell-based Assays (Need Lentivirus for stable line generation) |
| RNAi / Antisense | Ionis Pharmaceuticals | Hypertriglyceridemia, FCS | Target Knockdown Validation (Need sequence-verified siRNA) |